Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
capecitabine + tucidinostat
- Development stage
- Phase 2
- Lead developer
- Akeso
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of capecitabine, an antimetabolite chemotherapy agent, and tucidinostat, a selective histone deacetylase (HDAC) inhibitor. Tucidinostat selectively targets class I HDAC enzymes (HDAC-1, -2, and -3) and class IIb HDAC-10, modifying epigenetic mechanisms by promoting histone acetylation which leads to chromatin relaxation and transcriptional activation. This combination is being investigated for its potential synergistic effects in treating various types of breast cancer, including hormone receptor-positive/HER2-negative breast cancer and triple-negative breast cancer. The combination is often administered with capecitabine in a metronomic (low-dose, continuous) schedule.
- Other names
- chidamide + capecitabinetucidinostat and metronomic capecitabine
02
Targets
HDAC1 (Histone Deacetylase 1)HDAC10 (Histone Deacetylase 10)HDAC11 (Histone Deacetylase 11)HDAC2 (Histone deacetylase 2)HDAC3 (Histone Deacetylase 3)HDAC8 (Histone Deacetylase 8)
Beyond the preview
Go deeper on capecitabine + tucidinostat.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on capecitabine + tucidinostat.